Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection -- First ‘living medicine’ to treat antibiotic-resistant Pseudomonas aeruginosa infections in the lung, a leading cause of mortality in hospital settings – -- Data demonstrate treatment reduced lung...

ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program YONKERS, NY--(Marketwired - March 30, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...

ContraFect Announces Expanded Research Collaboration with The Rockefeller University to Identify Lysin Therapeutics Targeting Gram-negative Bacteria YONKERS, NY--(Marketwired - November 14, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...